Present and future of biologic drugs in primary Sjögren’s syndrome

References

• Mavragani CP, Moutsopoulos HM. Sjögren syndrome. CMAJ. 2014;186(15):E579–E586. DOI:10.1503/cmaj.122037
   PubMed Web of Science ®Google Scholar
• Qin B, Wang J, Yang Z, et al. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1983–1989. DOI:10.1136/annrheumdis-2014-205375
   PubMed Web of Science ®Google Scholar
• Bayetto K, Logan RM. Sjogren’s syndrome: a review of aetiology, pathogenesis, diagnosis and management. Aust Dent J. 2010;55(1):39–47. DOI:10.1111/j.1834-7819.2010.01197.x
   PubMed Web of Science ®Google Scholar
• Roescher N, Tak PP, Illei GG. Cytokines in Sjögren syndrome. Oral Dis. 2009;15(8):519–526. DOI:10.1111/j.1601-0825.2009.01582.x
   PubMed Web of Science ®Google Scholar
• Keystone EC. The utility of tumour necrosis factor blockade in orphan diseases. Ann Rheum Dis. 2004;63(suppl 2):ii79–ii83. DOI:10.1136/ard.2004.028498
   PubMed Web of Science ®Google Scholar
• Sisto M, D’amore M, Caprio S, et al. Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of salivary glands. Ann NY Acad Sci. 2009;1171:407–414. DOI:10.1111/j.1749-6632.2009.04688.x
   PubMed Web of Science ®Google Scholar
• Sisto M, Lisi S, Lofrumento DD, et al. TNF blocker drugs modulate human TNF-α-converting enzyme pro-domain shedding induced by autoantibodies. Immunobiology. 2010;215(11):874–883. DOI:10.1016/j.imbio.2009.11.005
   PubMed Web of Science ®Google Scholar
• Aoka K, Azuma M. Targeting TNF-α suppresses the production of MMP-9 in human salivary gland. Arch Oral Biol. 2013;58(12):1761–1768. DOI:10.1016/j.archoralbio.2013.09.004
   PubMed Web of Science ®Google Scholar
• Zandbelt MM, De Wilde P, Van Damme P, et al. Etanercept in the treatment of patients with primary Sjögren syndrome: a pilot study. J Rheumatol. 2004;31(1):96–101.
   PubMed Web of Science ®Google Scholar
• Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren syndrome: a twelve-week randomized, doble-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50(7):2240–2245. DOI:10.1002/art.20299
   PubMed Web of Science ®Google Scholar
• Mariette X, Ravaud P, Steinfel S, et al. Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomized, controlled trial of remicade in primary Sjögren’s syndrome (TRIPSS). Arthritis Rheum. 2004;50(4):1270–1276. DOI:10.1002/art.20146
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Demols P, Salmon I, et al. Notice of retraction of two articles (“infliximab in patients with primary Sjogren’s syndrome: a pilot study” and “infliximab in patients with primary Sjogren’s syndrome: one year followup”). Arthritis Rheum. 2013;65(3):814. DOI:10.1002/art.37942
   PubMed Web of Science ®Google Scholar
• Mavragan CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-alpha patway activation in patients with Sjögren’s syndrome trated with etanercept. Arthritis Rheum. 2007;56(1):3995–4004. DOI:10.1002/art.23062
   PubMed Web of Science ®Google Scholar
• Moutsopoulos NM, Katsifis GE, Angelov N, et al. Lack of efficacy of etanercept in Sjögren’s syndrome correlates with failed suppression of tumor necrosis factor alpha and systemic immune activation. Ann Rheum Dis. 2008;67(10):1437–1443. DOI:10.1136/ard.2007.077891
   PubMed Web of Science ®Google Scholar
• Youinou P, Devauchelle-Pensec V, Pers JO. Significance of B cells and B cell clonality in Sjogren’s syndrome. Arthritis Rheum. 2010;62(9):2605–2610. DOI:10.1002/art.27564
   PubMed Web of Science ®Google Scholar
• Shen L, Suresh L, Lindemann M, et al. Novel autoantibodies in Sjogren’s syndrome. Clin Immunol. 2012;145(3):251–255. DOI:10.1016/j.clim.2012.09.013
   PubMed Web of Science ®Google Scholar
• Tzioufas AG, Manoussakis MN, Costello R, et al. Cryoglobulinemia in autoimmune rheumatic diseases. Evidence of circulating monoclonal cryoglobulins in patient with primary Sjogrens’s syndrome. Arthritis Rheum. 1986;29:1098–1104.
   PubMed Web of Science ®Google Scholar
• Sugai S, Konda S, Shoraski Y, et al. Non-IgM monoclonal gammopathy in patients with Sjogrens’s syndrome. Am J Med. 1980;68:861–866.
   PubMed Web of Science ®Google Scholar
• Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjogren’s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90(2):766–775.
   PubMed Web of Science ®Google Scholar
• Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol. 2007;19:327–336. DOI:10.1016/j.coi.2007.04.008
   PubMed Web of Science ®Google Scholar
• Mackay F, Browning J. BAFF: a fundamental survival factor for B cells. Nature Rev Immunol. 2002;2(7):465–475. DOI:10.1038/nri844
   PubMed Web of Science ®Google Scholar
• Mackay F, Leung H. The role of the BAFF/APRIL system of T cell function. Semin Immunol. 2006;18(5):284–289. DOI:10.1016/j.smim.2006.04.005
   PubMed Web of Science ®Google Scholar
• He B, Chadburn A, Jou E, et al. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol. 2004;172(5):3268–3279.
   PubMed Web of Science ®Google Scholar
• D’Arbonneau F, Pers JO, Devauchelle-Pensec V, et al. BAFF-induced changes in B cell receptor-containing lipid rafts in Sjogren’s syndrome. Arthritis Rheum. 2006;54:115–126. DOI:10.1002/art.21478
   PubMed Web of Science ®Google Scholar
• Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BlyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest. 2002;109(1):59–68. DOI:10.1172/JCI14121
   PubMed Web of Science ®Google Scholar
• Vadacca M, Margiotta D, Sambataro D, et al. BAFF/APRIL pathway in Sjogren syndrome and systemic lupus erythematosus: relationship with chronic inflammation and disease activity. Reumatismo. 2010;62(4):259–265.
   PubMedGoogle Scholar
• Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjogren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford). 2013;52(2):276–281. DOI:10.1093/rheumatology/kes180
   PubMed Web of Science ®Google Scholar
• Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomized, double blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67(11):1541–1544. DOI:10.1136/ard.2007.083865
   PubMed Web of Science ®Google Scholar
• Pijpe J, Meijer JM, Bootsma H, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of Rituximab treatment in Sjogren’s syndrome. Arthritis Rheum. 2009;60(11):3251–3256. DOI:10.1002/art.24903
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of Rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the Autoimmune and Rituximab registry. Ann Rheum Dis. 2013;72(6):1026–1031. DOI:10.1136/annrheumdis-2012-202293
   PubMed Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960–968. DOI:10.1002/art.27314
   PubMed Web of Science ®Google Scholar
• Meiners PM, Arends S, Meijer JM, et al. Efficacy of retreatment with rituximab in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2015;33(3):443–444.
   PubMed Web of Science ®Google Scholar
• St Clair EW, Levesque MC, Prak ET, et al. Rituximab therapy for primary Sjogren’s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013;65(4):1097–1106. DOI:10.1002/art.37850
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160(4):233–242. DOI:10.7326/M13-1085 .
   PubMed Web of Science ®Google Scholar
• Bowman S, Everett C, Bombardieri M, et al. Preliminary results of a double-blind randomized trial of Rituximab anti-B-cell therapy in patients with primary Sjogren’s syndrome [abstract]. Arthritis Rheumatol. 2015;61(10). Available from: http://acrabstracts.org/abstract/preliminary-results-of-a-double-blind-randomised-trial-of-rituximab-anti-b-cell-therapy-in-patients-with-primary-sjogrens-syndrome/
   Google Scholar
• Cornec D, Devauchelle-Pensec V, Mariette X, et al. Development of the Sjögren’s syndrome responder index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology (Oxford). 2015;54(9):1699–1708. DOI:10.1093/rheumatology/kev114
   PubMed Web of Science ®Google Scholar
• Moeman RV, Arends S, Meiners PM, et al. EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomized controlled trial. Ann Rheum Dis. 2014;73(2):472–474. DOI:10.1136/annrheumdis-2013-203736
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Gottenberg JE, Jousse-Joulin S, et al. Which and how many patients should be included in randomized controlled trials to demonstrate the efficacy of biologics in primary Sjögren’s syndrome? PLoS One. 2015;10(9):e0133907. DOI:10.1371/journal.pone.0133907
   Google Scholar
• Cornec D, Costa S, Devauchelle-Pensec V, et al. Blood and salivary BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren’s syndrome. J Autoimmun. 2016;67:102–110. DOI:10.1016/j.jaut.2015.11.002
   PubMed Web of Science ®Google Scholar
• Delli K, Haacke EA, Kroese FG, et al. Towards personalized treatment in primary Sjögren’s syndrome: baseline parotid histopathology predics responsiveness to rituximab treatment. Ann Rheum Dis. 2016;0:1-6. [Epub ahead of print].
   Web of Science ®Google Scholar
• Cornec D, Costa S, Devauchelle-Pensec V, et al. Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren’s syndrome? Ann Rheum Dis. 2016;75:e33. DOI:10.1136/annrheumdis-2016-209300
   PubMed Web of Science ®Google Scholar
• Delli K, Haacke EA, Kroese FGM, et al. In primary Sjögren’s syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defineb by ESSDAI, but not by SSRI. Ann Rheum Dis. 2016;75:e34. DOI:10.1136/annrheumdis-2016-209317
   Google Scholar
• Hillen MR, Barone F, Radstake TRDJ, et al. Towards standardization of histopathologica assessments of germinal centers and lymphoid structures in primary Sjögren’s syndrome. Ann Rheum Dis. 2016;0:1.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Fabris M, Salvin S, et al. Controversies on rituximab therapy in Sjogren syndrome-associated lymphoproliferation. Int J Rheumatol. 2009;2009:424935. DOI:10.1155/2009/424935
   PubMedGoogle Scholar
• Pollard RP, Pijpe J, Bootsma H, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjögren’s syndrome: a retrospective clinical study. J Rheumatol. 2011;38(10):2198–2208. DOI:10.3899/jrheum.110077
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanized anti-CD22 antibody) in primary Sjogren’s syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8(4):R129. DOI:10.1186/ar2087
   PubMed Web of Science ®Google Scholar
• Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjogren’s syndrome: results of BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526–531. DOI:10.1136/annrheumdis-2013-203991
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12 months in primary Sjogren’s syndrome: the BELISS open-label phase II study. Reumatology (Oxford). 2015;54(12):2249–2256.
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by rituximab in Sjogren’s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol. 2014;32(4):490–494.
   PubMed Web of Science ®Google Scholar
• Cogollo E, Silva MA, Isenberg D. Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther. 2015;9:1331–1339. DOI:10.2147/DDDT.S71276
   PubMed Web of Science ®Google Scholar
• Genovese MC, Lee E, Satterwhite J, et al. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2013;72:1453–1480. DOI:10.1136/annrheumdis-2012-202864
   PubMed Web of Science ®Google Scholar
• Stohl W, Merrill JT, Looney J, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase1a and phase 1b trials. Arthritis Res Ther. 2015;17(1):215. DOI:10.1186/s13075-015-0741-z
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Seshasayee D, Chang W, et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathil. 2006;168(2):476–489. DOI:10.2353/ajpath.2006.050600
   PubMed Web of Science ®Google Scholar
• Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39(6):1003–1018. DOI:10.1016/j.immuni.2013.11.010
   PubMed Web of Science ®Google Scholar
• Dubost JJ, Perrier S, Afane M, et al. IL-1 receptor antagonist in saliva; characterization in normal saliva and reduced concentration in Sjögren’s Syndrome (SS). Clin Exp Immunol. 1996;106(2):237–242.
   PubMed Web of Science ®Google Scholar
• Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry eye disease. Invest Ophtalmol Vis Sci. 2001;42(10):2283–2292.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm. 2015;2015:194864. DOI:10.1155/2015/125380
   PubMed Web of Science ®Google Scholar
• Harboe E, Tjensvoll AB, Vefring HK, et al. Fatigue in primary Sjögren’s syndrome —a link to sickness behavior in animals? Brain Behav Immun. 2009;23(8):1104–1108. DOI:10.1016/j.bbi.2009.06.151
   PubMed Web of Science ®Google Scholar
• Norheim KB, Harboe E, Göransson LG, et al. Interleukin-1 inhibition and fatigue in primary Sjögren’s syndrome —a double blind, randomized clinical trial. Plos One. 2012;7(1):e30123. DOI:10.1371/journal.pone.0030123
   PubMed Web of Science ®Google Scholar
• Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. Br J Clin Pharmacol. 2011;71(5):639–641. DOI:10.1111/j.1365-2125.2011.03958.x
   PubMed Web of Science ®Google Scholar
• Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune disease. N Eng J Med. 1996;335(18):1369–1377. DOI:10.1056/NEJM199610313351807
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanism of T-cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242. DOI:10.1038/nri3405
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54(9):2807–2816. DOI:10.1002/art.22070
   PubMed Web of Science ®Google Scholar
• Oxholm P, Daniels TE, Bendtzen K. Cytokine expression in labial salivary glands from patients with primary Sjogren’s syndrome. Autoimmunity. 1992;12:185–191.
   PubMed Web of Science ®Google Scholar
• Matsumura R, Umemiya K, Goto T, et al. Glandular and extraglandular expression of costimulatory molecules in patients with Sjogren’s syndrome. Ann Rheum Dis. 2001;60:473–482.
   PubMed Web of Science ®Google Scholar
• Adler S, Korner M, Forger F, et al. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjogren syndrome: a pilot study. Arthritis Care Res (Hoboken). 2013;65:1862–1868. DOI:10.1002/acr.22052
   PubMed Web of Science ®Google Scholar
• Meiners PM, Vissink A, Kroese FG, et al. Abatacept treatment reduces disease activity in early primary Sjogren’s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014;73(7):1393–1396. DOI:10.1136/annrheumdis-2013-204653 .
   PubMed Web of Science ®Google Scholar
• Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res. 2006;298:7–15. DOI:10.1007/s00403-006-0660-6
   PubMed Web of Science ®Google Scholar
• Tran D, Bebris L, Shevach E, et al. Efalizumab down-regulates CD25 expression of FOXP3+ regulatory T cells and exacerbates the autoimmunity in primary Sjogren’s syndrome. J Immunol. 2010;184(suppl 1):96.4. DOI:10.4049/jimmunol.0902016
   PubMed Web of Science ®Google Scholar
• Molloy ES, Calabrese LH. Therapy: targeted but not trouble-free: efalizumab and PML. Nat Rev Rheumatol. 2009;5(8):418–419. DOI:10.1038/nrrheum.2009.142
   PubMed Web of Science ®Google Scholar
• Aroson R, Gottlieb PA, Christiansen JS, et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care. 2014;37(10):2746–2754. DOI:10.2337/dc13-0327
   PubMed Web of Science ®Google Scholar
• Youinou P, Pers JO. Disturbance of cytokine networks in Sjogren’s syndrome. Arthr Res Ther. 2011;13(4):227. DOI:10.1186/ar3348
   PubMed Web of Science ®Google Scholar
• Grisius MM, Bermudez DK, Fox PC. Salivary and serum interleukin 6 in primary Sjogren’s syndrome. J Rheumatol. 1997;24(6):1089–1091.
   PubMed Web of Science ®Google Scholar
• Yoon KC, Jeong IY, Park YG, et al. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007;26(4):431–437. DOI:10.1097/ICO.0b013e31803dcda2
   PubMed Web of Science ®Google Scholar
• Hulkkonen J, Pertovaara M, Antonen J, et al. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren’s syndrome and correlate with the clinical manifestation of the disease. Rheumatology (Oxford). 2001;40(6):656–661.
   PubMed Web of Science ®Google Scholar
• Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 2009;69(5):609–632. DOI:10.2165/00003495-200969050-00007
   PubMed Web of Science ®Google Scholar
• Justet A, Ottaviani S, Dieudé P, et al. Tocilizumab for refractory organising pneumonia associated with Sjogren disease. BMJ Case Rep. 2015;2015. doi:10.1136/bcr-2014-209076
   PubMedGoogle Scholar
• Komai T, Shoda H, Yamaguchi K, et al. Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: a case report. Mod Rheumatol. 2016;26(2):294–296. DOI:10.3109/14397595.2013.861333
   PubMed Web of Science ®Google Scholar
• Efficacy of Tocilizumab in primary Sjögren’s syndrome. [Updated 2016 Aug]. Available from: http://www.trialdetails.com/detail/NCT01782235/Efficacy-of-Tocilizumab-in-Primary-Sj%C3%B6grens-Syndrome
   Google Scholar
• Alunno A, Carubbi F, Bartoloni E, et al. Unmasking the pathogenic role of IL-17 axis in primary Sjögren’s syndrome: a new era for therapeutic targeting? Autoimmunity Rev. 2014;13:1167–1173. DOI:10.1016/j.autrev.2014.08.022
   PubMed Web of Science ®Google Scholar
• Blaho VA, Buczynski MW, Dennis EA, et al. Cyclooxygenase-1 orchestrates germinal center formation and antibody class-switch via regulation of IL-17. I Immunol. 2009;183(9):5644–5653. DOI:10.4049/jimmunol.0901499
   PubMed Web of Science ®Google Scholar
• Ferretti E, Di Carlo E, Ognio E, et al. Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma. Oncoimmunology. 2015;4(10):e1030560. DOI:10.1080/2162402X.2015.1008371
   Google Scholar
• Lin X, Rui K, Deng L, et al. Th17 cells play a critical role in the development of experimental Sjögren’s syndrome. Ann Rheum Dis. 2014;74(6):1302–1310. DOI:10.1136/annrheumdis-2013-204584
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, et al. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren’s syndrome. Rheumatology (Oxford). 2014;53(7):1313–1320. DOI:10.1093/rheumatology/keu004
   PubMed Web of Science ®Google Scholar
• Alunno A, Bistoni O, Caterbi S, et al. Serum interleukin-17 in primary Sjögren’s syndrome: association with disease duration and parotid gland swelling. Clin Exp Rheumatol. 2015;33(1):129.
   PubMed Web of Science ®Google Scholar
• Mieliauskaite D, Dumalakiene I, Rugiene R, et al. Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjögren’s syndrome. Clin Dev Immunol. 2012;2012:187258. DOI:10.1155/2012/187258
   PubMedGoogle Scholar
• Alunno A, Carubbi F, Bistoni O, et al. CD4-CD8- T cells in primary Sjögren’s syndrome: association with the extend of glandular involvement. J Autoimmun. 2014;51:38–43. DOI:10.1016/j.jaut.2014.01.030
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing Brodalumab with Ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–1328. DOI:10.1056/NEJMoa1503824
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-Interleukin-17 monoclonal antibody Ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190–1199. DOI:10.1056/NEJMoa1109997
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371:326–338. DOI:10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of Rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75(1):196–202. DOI:10.1136/annrheumdis-2014-206090
   PubMed Web of Science ®Google Scholar
• Maria NI, Vogelsang P, Versnel MA. The clinical relevance of animal models in Sjögren’s syndrome: the interferon signature from mouse to man. Arthritis Res Ther. 2016;17:172. DOI:10.1186/s13075-015-0678-2
   Web of Science ®Google Scholar
• Voller J, Tluk S, Schmitz C, et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med. 2005;202(11):1575–1585. DOI:10.1084/jem.20051696
   PubMed Web of Science ®Google Scholar
• Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigen activate B cells by combined B cell antigen receptor/Toll-like receptor 7. J Exp Med. 2005;202(9):1171–1177. DOI:10.1084/jem.20050630
   PubMed Web of Science ®Google Scholar
• Pawar RD, Ramanjaneyulu A, Kulkarni OP, et al. Inhibition of Toll-like Receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol. 2007;18:1721–1731. DOI:10.1681/ASN.2006101162
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Meeker T, Chan JH, et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol. 2007;37:3582–3586. DOI:10.1002/eji.200737815
   PubMed Web of Science ®Google Scholar
• Cummins MJ, Papas A, Kammer GM, et al. Treatment of primary Sjogren’s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum. 2003;49(4):585–593. DOI:10.1002/art.11199
   PubMed Web of Science ®Google Scholar
• Youn SW, Tsai TF, Theng C, et al. The MARCOPOLO study of Ustekinumab utilization and efficacy in a real-world settin: treatment of patients with plaque psoriasis in Asia-Pacific countries. Ann Dermatol. 2016;28(2):222–231. DOI:10.5021/ad.2016.28.2.222
   PubMed Web of Science ®Google Scholar
• Panaccione R, Sandborn WJ, Gordon GL, et al. Briakinumab for treatment of Crohn’s disease: results of a randomized trial. Inflamm Bowel Dis. 2015;21(6):1329–1340. DOI:10.1097/MIB.0000000000000366
   PubMed Web of Science ®Google Scholar
• Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of Guselkumab versus Adalimumab for plaque psoriasis. N Engl J Med. 2015;373:136–144. DOI:10.1056/NEJMoa1501646
   PubMed Web of Science ®Google Scholar
• Vosters JL, Landek-Salgado MA, Yin H, et al. IL-12 induces salivary gland dysfunction, providing a new mouse model of Sjogren’s syndrome. Arthritis Rheum. 2009;60(12):3633–3641. DOI:10.1002/art.24980
   PubMed Web of Science ®Google Scholar
• Nquyen CQ, Hu MH, Li Y, et al. Salivary gland tissue expression of interleukin-23 and interleukin-12 in Sjogren’s syndrome: findings in humans and mice. Arthritis Rheum. 2008;58(3):734–743. DOI:10.1002/art.23214
   PubMed Web of Science ®Google Scholar
• Bombardieri M, Pitzalis C. Ectopic lymphoid neogenesis and lymphoid chemokines in Sjogren’s syndrome: at the interplay between chronic inflammation, autoimmunity and lymphomagenesis. Curr Pharm Biotechnol. 2012;13(10):1989–1996.
   PubMed Web of Science ®Google Scholar
• Nocturne G, Seror R, Fogel O, et al. CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sjögren’s syndrome. Arthritis Rheumatol. 2015;67(12):3226–3233. DOI:10.1002/art.39315
   PubMed Web of Science ®Google Scholar
• Gottemberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. Jama. 2014;312(3):249–258. DOI:10.1001/jama.2014.7682
   PubMed Web of Science ®Google Scholar
• Safety, pharmacokinetics and preliminary efficacy study of CFZ533 in patients with primary Sjögren’s Syndrome. [Updated 2016 Mar]. Available from: https://clinicaltrials.gov/ct2/show/NCT02291029?term=Sjogren%27s+syndrome&rank=2
   Google Scholar
• Safety, pharmacokinetics, and preliminary efficacy study of CDZ137 in patiens with Primary Sjögren’s Syndrome. [Updated 2016 May]. Available from: https://clinicaltrials.gov/ct2/show/NCT02775916?term=Sjogren%27s+syndrome&rank=8
   Google Scholar
• UCB proof of concept study in patients with primary Sjögren’s syndrome. [Updated 2015 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02610543?term=UCB5857+AND+Sjogren&rank=1
   Google Scholar
• A phase 2a, randomized, placebo controlled, study to evaluate the safety and efficacy of AMG557/MEDI5872 in primary Sjögren’s syndrome. [Updated 2016 Mar]. Available from: https://clinicaltrials.gov/ct2/show/NCT02334306?term=Sjogren%27s+syndrome&rank=13
   Google Scholar
• A study to assess the efficacy of RO5459072 in participants with primary Sjögren’s syndrome. [Updated 2016 Aug]. Available from: https://clinicaltrials.gov/ct2/show/NCT02701985?term=sjogren%27s+syndrome&rank=12
   Google Scholar
• A safety and efficacy study of 552-02 in subjects with dry mouth associated with Sjögren’s syndrome. [Updated 2014 Jul]. Available from: https://clinicaltrials.gov/ct2/show/NCT00852839?term=sjogren%27s+syndrome&rank=4
   Google Scholar
• A phase II study with low–dose recombinant human IL-2 for the treatment of primary Sjögren’s syndrome. [Updated 2015 Jun]. https://clinicaltrials.gov/ct2/show/NCT02464319?term=sjogren%27s+syndrome&rank=27
   Google Scholar
• Study of NGX267 oral capsules in patients with xerostomia associated with Sjögren’s syndrome. [Updated 2009 Jan]. Available from: https://clinicaltrials.gov/ct2/show/NCT00637793?term=sjogren%27s+syndrome&rank=40
   Google Scholar
• Safety and efficacy study of subcutaneous Belimumab and intravenous Rituximab co-administration in subjects with primary Sjögren’s syndrome. [Updated 2016 Aug]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02631538?term=sjogren+syndrome&rank=11
   Google Scholar
• Efficacy and safety of abatacept in patients with primary Sjögren’s syndrome (ASAPIII). [Updated 2015 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02067910
   Google Scholar
• PD of VAY736 in patients with primary Sjögren’s Syndrome (CVAY736X2201). [Updated 2016 Feb]. Available from: https://clinicaltrials.gov/ct2/show/NCT02149420?term=Sjogren%27s+syndrome&rank=9
   Google Scholar
• A study of LY3090106 in participants with Sjögren’s Syndrome (SS). [Updated 2016 Aug]. Available from: https://clinicaltrials.gov/ct2/show/NCT02614716?term=Sjogren%27s+syndrome&rank=46
   Google Scholar
• Brito Zeron P, Ramon-Casals M, Bove A, et al. Predicting adverse outcomes in primary Sjögren syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007;46(8):1359–1362. DOI:10.1093/rheumatology/kem079
   PubMed Web of Science ®Google Scholar
• Nocturne G, Virone A, Wan-Fai NG, et al. Rheumatoid Factor and disease activity are independent predictors of lymphoma in primary Sjögren’s syndrome. Arthritis Reumatol. 2016;68(4):977–985. DOI:10.1002/art.39518
   PubMed Web of Science ®Google Scholar
• Baimpa E, Dahabreh H, Voulgarelis M, et al. Hematologic manifestation and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009;88(5):284–293. DOI:10.1097/MD.0b013e3181b76ab5
   PubMed Web of Science ®Google Scholar
• Chung JK, Kim MK, Wee WR. Prognostic factors fot the clinical severity of keratoconjunctivitis sicca in patients with Sjögren syndrome. Br J Ophthalmol. 2012;96(2):240–245. DOI:10.1136/bjo.2011.202812
   PubMed Web of Science ®Google Scholar
• Bergum B, Koro C, Delaleu N, et al. Antibodies against carbamylated proteins are present in primary Sjögren syndrome and are associated with disease severity. Ann Rheum Dis. 2016;75(8):1494–1500. DOI:10.1136/annrheumdis-2015-207751
   PubMed Web of Science ®Google Scholar
• Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69(6):1103–1109. DOI:10.1136/ard.2009.110619
   PubMed Web of Science ®Google Scholar
• Seror R, Ravaud P, Mariette X, et al. EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary sjogren’s syndrome. Ann Rheum Dis. 2011;70(6):968–972. DOI:10.1136/ard.2010.143743
   PubMed Web of Science ®Google Scholar
• Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjogren’s syndrome with EULAR primary Sjogren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75(2):382–389. DOI:10.1136/annrheumdis-2014-206008
   PubMed Web of Science ®Google Scholar